Inflammatory bowel syndrome (IBS) is the most common gastrointestinal disorder seen by primary care providers, yet it remains a source of frustration for both patients and physicians. Recent advances in our understanding of the etiology and pathophysiology of IBS have led to new diagnostic guidelines that avoid unnecessary testing so that IBS is no longer a diagnosis of exclusion. Treatment options are varied and evolving and include pharmacologic and non-pharmacologic options depending on the subtype of IBS and individual patient characteristics. This archived symposium will provide participants with the opportunity to assess new data and remaining challenges in the diagnosis and treatment of patients with IBS via interactive case scenarios.
Find the latest free continuing medical education courses in gastroenterology to help you receive the CME credits you need.
The treatment of HCV has undergone a dramatic evolution in the last several years. Whereas traditional interferon-based therapy for HCV was limited by poor efficacy and a heavy burden of side effects, interferon-free antiviral regimens are now available, offering new options for patients and altering the approach to this serious disease. The rapid pace of drug research, development, and approval requires frequent updates to treatment guidelines and leaves many clinicians wondering when, in whom, and how to manage chronic HCV infection.